Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021

SELL
$16.59 - $33.89 $2.07 Million - $4.22 Million
-124,594 Closed
0 $0
Q4 2020

Jan 19, 2021

BUY
$27.5 - $37.92 $1.15 Million - $1.58 Million
41,691 Added 50.29%
124,594 $5.39 Million
Q3 2020

Nov 16, 2020

SELL
$34.44 - $43.75 $12.6 Million - $16.1 Million
-366,943 Reduced 81.57%
82,903 $4.47 Million
Q2 2020

Jul 17, 2020

BUY
$27.12 - $45.97 $7.34 Million - $12.4 Million
270,718 Added 151.13%
449,846 $27.5 Million
Q1 2020

Apr 16, 2020

BUY
$26.16 - $63.5 $928,104 - $2.25 Million
35,478 Added 24.7%
179,128 $8.23 Million
Q4 2019

Feb 14, 2020

BUY
$46.96 - $61.67 $4.7 Million - $6.17 Million
100,116 Added 229.97%
143,650 $12.6 Million
Q3 2019

Nov 14, 2019

SELL
$59.47 - $93.1 $3.8 Million - $5.95 Million
-63,862 Reduced 59.46%
43,534 $4 Million
Q2 2019

Aug 14, 2019

SELL
$75.84 - $105.21 $3.02 Million - $4.18 Million
-39,762 Reduced 27.02%
107,396 $13.7 Million
Q1 2019

May 07, 2019

SELL
$64.44 - $104.11 $138,159 - $223,211
-2,144 Reduced 1.44%
147,158 $23.2 Million
Q4 2018

Jan 25, 2019

BUY
$59.1 - $93.26 $4.74 Million - $7.49 Million
80,287 Added 116.33%
149,302 $14.8 Million
Q3 2018

Oct 30, 2018

SELL
$88.86 - $117.49 $2.3 Million - $3.03 Million
-25,831 Reduced 27.23%
69,015 $10.1 Million
Q2 2018

Aug 03, 2018

BUY
$99.64 - $127.59 $4.32 Million - $5.53 Million
43,365 Added 84.23%
94,846 $14.9 Million
Q1 2018

Apr 30, 2018

SELL
$105.8 - $150.94 $4.83 Million - $6.89 Million
-45,620 Reduced 46.98%
51,481 $8.79 Million
Q4 2017

Jan 18, 2018

SELL
$81.25 - $130.7 $4.65 Million - $7.49 Million
-57,288 Reduced 37.11%
97,101 $17.3 Million
Q3 2017

Oct 31, 2017

BUY
$57.74 - $91.42 $8.91 Million - $14.1 Million
154,389
154,389 $21.2 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $75.6M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Frontier Capital Management CO LLC Portfolio

Follow Frontier Capital Management CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frontier Capital Management CO LLC with notifications on news.